Literature DB >> 12494278

Is sildenafil failure in men after radical retropubic prostatectomy (RRP) due to arterial disease? Penile duplex Doppler findings in 174 men after RRP.

A McCullough1, K Woo, S Telegrafi, H Lepor.   

Abstract

Sildenafil is frequently the first-line treatment for post-radical retropubic prostatectomy (RRP) erectile dysfunction (ED) with maximum treatment satisfaction rates of 43%-80%. The etiology of erectile dysfunction after RRP has been attributed to psychogenic, vascular, veno- occlusive or nerve injury causes. The purpose of this study was to gain insight into the penile duplex Doppler arterial parameters in men with ED after RRP who failed sildenafil. The purpose was to assess whether sildenafil failure after RRP is associated with underlying corporal arterial disease. A total of 174 consecutive men presenting with sildenafil refractory ED after nerve-sparing RRP underwent color duplex penile Doppler evaluation with vasoactive injection. Mean age was 59.6 y and mean time from surgery was 11.6 months. Some 81% (141/174) of the men had no pre-operative ED (PED). Significant differences in penile duplex Doppler parameters for arterial disease were seen between men with and without PED. In men without PED, 19% (27/141) manifested arterial insufficiency. However, in men with PED, 50% (16/33) demonstrated arterial disease. Nerve sparing status did not affect the presence of arterial disease. Sildenafil refractory erectile dysfunction after RRP in men without PED is not predominantly associated with penile Doppler parameters consistent with arterial insufficiency.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12494278     DOI: 10.1038/sj.ijir.3900909

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  8 in total

1.  Renewing intimacy: advances in treating erectile dysfunction postprostatectomy.

Authors:  Herbert Lepor; Andrew McCullough; Jason D Engel
Journal:  Rev Urol       Date:  2008

2.  PDE-5 Inhibitor Therapy for Erectile Dysfunction Secondary to Nerve-Sparing Radical Retropubic Prostatectomy.

Authors:  Harin Padma-Nathan
Journal:  Rev Urol       Date:  2005

3.  Advances in the Management of Post-Radical Prostatectomy Erectile Dysfunction: Treatment Strategies When PDE-5 Inhibitors Don't Work.

Authors:  Bruce R Kava
Journal:  Rev Urol       Date:  2005

4.  Sexual dysfunction after radical prostatectomy.

Authors:  Andrew R McCullough
Journal:  Rev Urol       Date:  2005

5.  Fibrosis and loss of smooth muscle in the corpora cavernosa precede corporal veno-occlusive dysfunction (CVOD) induced by experimental cavernosal nerve damage in the rat.

Authors:  Monica G Ferrini; Istvan Kovanecz; Sandra Sanchez; Chiome Umeh; Jacob Rajfer; Nestor F Gonzalez-Cadavid
Journal:  J Sex Med       Date:  2008-12-02       Impact factor: 3.802

Review 6.  Erectile dysfunction following prostatectomy: prevention and treatment.

Authors:  Ahmed Magheli; Arthur L Burnett
Journal:  Nat Rev Urol       Date:  2009-08       Impact factor: 14.432

Review 7.  Toward a new 'EPOCH': optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction.

Authors:  R Sadovsky; G B Brock; S W Gutkin; S Sorsaburu
Journal:  Int J Clin Pract       Date:  2009-08       Impact factor: 2.503

Review 8.  Erectile dysfunction secondary to nerve-sparing radical retropubic prostatectomy: comparative phosphodiesterase-5 inhibitor efficacy for therapy and novel prevention strategies.

Authors:  Harin Padma-Nathan; Andrew McCullough; Christopher Forest
Journal:  Curr Urol Rep       Date:  2004-12       Impact factor: 2.862

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.